Trial Profile
A Phase III, Double-blind, Placebo-controlled, Multi-center International Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Stages II and III Non-small Cell Lung Cancer (AEGEAN)
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 02 May 2024
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Carboplatin; Cisplatin; Gemcitabine; Paclitaxel; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms AEGEAN
- Sponsors AstraZeneca; AstraZeneca AB; AstraZeneca India; AstraZeneca KK
- 10 Jan 2024 This trial has been Completed in Bulgaria, According to European Clinical Trials Database record.
- 24 Oct 2023 Results of exploratory analyses assessing associations of ctDNA clearance and pathological response with neoadjuvant treatment in patients with resectable NSCLC, presented at the 48th European Society for Medical Oncology Congress.
- 23 Oct 2023 Results published in the New England Journal of Medicine